CurifyLabs raises €12 million Series A to bring 3D-printed personalised medicine to scale

CurifyLabs, a Finnish medtech founded in 2021, has closed a €12 million Series A ($14 million) co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment) and Lifeline Ventures. The company, led by founder and CEO Charlotta Topelius, develops cloud-based software and hardware systems that enable hospitals and compounding pharmacies to manufacture individually dosed, 3D-printed medications at clinical scale — a technology that addresses one of pharmacy's most persistent structural problems: the gap between what patients statistically need and what individual patients actually respond to.

What 3D-printed medicine means in practice

Compounding pharmacies — facilities that produce medications tailored to individual patients rather than standard formularies — exist in most healthcare systems but operate with significant manual overhead. Formulating, mixing, and dispensing a custom drug dose for a single patient is time-intensive and prone to error at scale. CurifyLabs replaces the manual steps with a digital workflow: a clinician specifies a dose and formulation, the system generates a manufacturing batch, and a pharmaceutical-grade 3D printer deposits the medication to a precisely controlled specification.

The technology is not at pilot stage — CurifyLabs has already deployed systems into clinical environments. The Series A is capital for moving from early clinical deployments to commercial scale. The target population is real: children, elderly patients, and anyone on a complex medication regime frequently require doses and formulations that the standard pharmaceutical supply chain cannot efficiently produce. Exact dosing for paediatric patients — where weight-adjusted dosing requires fractions of a standard adult tablet — is the archetypal use case.

Sandwater's second bet in a week

The co-lead is worth examining. Sandwater, the Norwegian deep-science fund, backed Alva Industries in this site's recent coverage — a Norwegian company spending its Series A proving a fundamentally different architecture for electric motors. CurifyLabs is the fund's second ProYarn-covered investment in under a week, and the two bets share a structural characteristic: both are capital-intensive, long-to-scale plays where the hard part is manufacturing, not software.

HealthCap, the Swedish life-sciences fund that has backed a string of European biotech and medtech companies to exit, brings the clinical and regulatory expertise that a medical-device journey through the FDA and European regulators requires. Tesi, Finland's state-owned industrial investment fund, and Lifeline Ventures round out the syndicate.

The US expansion bet is deliberate. American compounding pharmacies operate under a relatively permissive regulatory framework compared with Europe's fragmented member-state rules, making the US the right first international market for a platform still building its commercial references. Topelius frames the round simply: "This investment reflects the conviction our partners have in what we're building." How long before the European regulatory environment — where CurifyLabs' Finnish base provides one possible template — standardises enough to support a continent-wide roll-out is the 18-month question the Series A is not yet designed to answer.